Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collecte...

Full description

Bibliographic Details
Main Authors: Diletta Valentini, Nicola Cotugno, Vittorio Scoppola, Chiara Di Camillo, Luna Colagrossi, Emma Concetta Manno, Carlo Federico Perno, Cristina Russo, Paolo Palma, Paolo Rossi, Alberto Villani
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/11/3/694